The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Impact of primary biliary cirrhosis on perceived quality of life: The UK-PBC national study
Open accessAbstract
Primary biliary cirrhosis (PBC) has a complex clinical phenotype, with debate about the extent and specificity of frequently described systemic symptoms such as fatigue. The aim of this study was to use a national patient cohort of 2,353 patients recruited from all clinical centers in the UK to explore the impact of disease on perceived life quality. Clinical data regarding diagnosis, therapy, and biochemical status were collected and have been reported previously. Detailed symptom phenotyping using recognized and validated symptom assessment tools including the PBC-40 was also undertaken and is reported here. Perception of poor quality of life and impaired health status was common in PBC patients (35% and 46%, respectively) and more common than in an age-matched and sex-matched community control group (6% and 15%, P < 0.0001 for both). Fatigue and symptoms of social dysfunction were associated with impaired perceived quality of life using multivariate analysis. Fatigue was the symptom with the greatest impact. Depression was a significant factor, but appeared to be a manifestation of complex symptom burden rather than a primary event. Fatigue had its greatest impact on perceived quality of life when accompanied by symptoms of social dysfunction, suggesting that maintenance of social networks is critical for minimizing the impact of fatigue. Conclusion : The symptom burden in PBC, which is unrelated to disease severity or ursodeoxycholic acid response, is significant and complex and results in significant quality of life deficit. The complexity of symptom burden, and its lack of relation to disease severity and treatment response, suggest that specific approaches to symptom management are warranted that address both symptom biology and social impact. (Hepatology 2013;58:-)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The symptoms associated with PBC impact on QoL, and include: cholestatic pruritus, sicca complex, abdominal discomfort and fatigue [29,30].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigued patients perceive a poor QoL compared to controls, and their levels of social engagement are lower [29,30].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although fatigue is not specific to PBC, it is frequently reported by patients (over 50%) and when severe, as it is in 20% of patients, is a significant cause of QoL impairment.12 171 205–208”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [171]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigue has been shown to be the symptom with the biggest impact on patients. Fatigued patients perceive a poor QoL compared with controls and their levels of social engagement are lower.171 219”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [171]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The symptoms associated with PBC have a significant impact on QoL for patients [29], and can be broad.”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Fatigued patients perceive a poor QoL compared to controls, and their levels of social engagement are lower [29,30].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“The symptoms of PBC significantly impair quality of life (182) and do not typically improve with UDCA or OCA treatment.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [182]
The cited source says what the claim attributes to it.
In the citing paper
“The symptoms associated with PBC are important and have a significant impact on life quality for patients.171”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [171]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 2,016
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
(2015) · Elsevier eBooks · doi:10.1016/b978-0-323-37755-3.50202-6 · Cited by 808
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 1×
“Of those who had received UDCA for at least a year 79% (63% of the whole patient population) met the Paris criteria for adequate treatment response.(21) Response to UDCA was age-related, with younger presenting and male patients less likely to respond.”
MethodGenome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis
The UK PBC Consortium, Mells, G. F., The Wellcome Trust Case Control Consortium 3, Floyd, J. A. B., Morley, K. I., Cordell, H. J., Franklin, C. S., Shin, S.-Y., Heneghan, M. A., Neuberger, J. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.789 · Cited by 464
Self-citationThe effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis
Corpechot, C., Carrat, F., Bahr, A., Chrétien, Y., Poupon, R., & Poupon, R. Y. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.009 · Cited by 392
Carbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.005 · Cited by 386
Self-citationHealth-related quality of life in chronic liver disease: the impact of type and severity of disease
Younossi, Z. M., Boparai, N., Price, L. L., Kiwi, M. L., McCormick, M., & Guyatt, G. H. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03956.x · Cited by 342
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–226 of 226
Skat-Rørdam, P. A., Eliasson, J., Kjær, M. S., Jeppesen, P. B., & Ytting, H. (2023) · Minerva Gastroenterology · doi:10.23736/s2724-5985.23.03206-0
The Evolution of Pruritus Management for People with Primary Biliary Cholangitis
Roberts, E. (2024) · EMJ Hepatology · doi:10.33590/emjhepatol/11000003
Steinmann, S., & Schramm, C. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01674-7
Khakoo, N. S., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00039-4
Iqirvo for primary biliary cholangitis – efficacy, safety, and future directions
Saleem, R., Shakeel, A., Riaz, R., Noman, F., & Nasser, N. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003183 · Cited by 1
Buck, L., Herzberg, J., Lenaert, B., Löwe, B., Hartl, J., Schramm, C., & Toussaint, A. C. (2025) · Scientific Reports · doi:10.1038/s41598-025-16191-2
Du, Q., Han, Y., & Pan, P. (2025) · Medicine · doi:10.1097/md.0000000000044731
Böttcher, M. H., Bossen, L., Mellemkjær, A., Holland‐Fischer, P., Hansen, J. B., Møller, H. J., & Grønbæk, H. (2025) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2602520
Curto, A., Tanturli, M., Iamello, R. G., Rossi, P., Mengozzi, G., Dei, L., Mello, T., Innocenti, T., Dragoni, G., Galli, A., et al. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i2.114206
Düll, M. M., & Kremer, A. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34172-4.00031-8
Almishri, W., Dunn, J. F., & Swain, M. G. (2026) · Molecular Brain · doi:10.1186/s13041-026-01302-5
Chung, A. H.-L., Tan, J. J.-R., Yap, R. X. J., Loo, J. H., Tay, W. X., Singh, C. L., Ong, S. J., Low, A. Y. J., Lin, Y., Lytvyak, E., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000940
The Scientific Basis of Cholestatic Liver Disease and Its Symptom Complex
Nguyen, H. H., & Swain, M. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.001
American Association for the Study of Liver Diseases, & EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (2026) · Hepatology · doi:10.1097/hep.0000000000001791
The interplay of gut microbiota and energy homeostasis in obesity-related diseases
Ruan, J., & Kao, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40306-4.00009-0
Takeuchi, A., Komori, A., Kawata, K., Yoshida, O., Tanaka, A., Abe, K., Fujinaga, Y., Namisaki, T., Kimura, N., Katsumi, T., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70246
Shamseddine, N., Yang, H., Zhang, S., Ye, D., Seshasayee, S. M., Chen, J., Kumar, S. R., & Kowdley, K. V. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0172
Kumar, S., Shamseddine, N., Yang, H., Zhang, S., Chen, J., & Kowdley, K. V. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0179
Efficacy, symptoms, and safety of second-line PBC therapies: a network meta-analysis
Zhao, W., Wu, Z., Kou, Q., Qiao, S., Liu, Z., & Zhang, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1859342
Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Álvares‐da‐Silva, M. R., Andreoné, P., Arrese, M. A., Corpechot, C., Elbeshbeshy, H. A., Francque, S., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.08.016
Self-citationPruritus scores and gamma glutamyl transferase pattern in calcular and malignant biliary obstruction
Said, E., Elmashad, M. E., NEKLAWI, M. S. M. S. E., Shams, G. M., Mahran, E. E. M. O., Emara, M., & Abdelhamid, M. S. (2026) · Egyptian Liver Journal · doi:10.1186/s43066-026-00545-0
Patient pathways for rare liver diseases: a European template developed by ERN RARE-LIVER
Raevens, S., Duijzer, R., Fodor, A., Johnson, M. B., Issa, N., Pénisson, S., Patel, S., Bertolini, A., Teemer, C. A. J., Ramier, C., et al. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04556-3
Levy, C., Gibbons, D. C., Abner, S. C., Friedler, H. S., Dhirishiya, P., Vadlamudi, H. C., Earley-Valovic, V., Coutinho, A., Hagan, K. A., Begaj, K., et al. (2026) · Liver International · doi:10.1111/liv.70809
Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis
Halilbasic, E., Tatscher, E., Aigner, E., Burghart, L., Graziadei, I. W., Hametner‐Schreil, S., Hofer, B., Hofer, H., Maieron, A., Mandorfer, M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02798-6
van der Meer, A. J., & Trivedi, P. J. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch20
Dialing up success: next generation treatments in primary biliary cholangitis
Cançado, G. G. L., & Hirschfield, G. M. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.10.012
Metadata
- Authors
- Mells, G. F., Pells, G., Newton, J. L., Bathgate, A. J., Burroughs, A. K., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., Alexander, G. J., & Jones, D. E. J.
- Affiliations
- University of Cambridge (GB)
- Newcastle University (GB)
- NIHR Newcastle Biomedical Research Centre (GB)
- Edinburgh Royal Infirmary (GB)
- The Royal Free Hospital (GB)
- King's College Hospital NHS Foundation Trust (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- Corresponding author
- Jones, David E.J.
- ORCID
- Venue
- Hepatology
- Published
- 2013-07
- Volume
- 58
- Issue
- 1
- Pages
- 273-283
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2093292173
- Semantic Scholar
- c3f7cee219b4024ce1b44b26b30d2b5f4b77d7e4
- Cited by
- 227
- References
- 29
- Citations by year
- 2026: 27 · 2025: 27 · 2024: 16 · 2023: 17 · 2022: 15 · 2021: 19 · 2020: 15 · 2019: 22 · 2018: 22 · 2017: 12 · 2016: 9 · 2015: 15 · 2014: 8 · 2013: 2
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Royal Devon and Exeter NHS Foundation Trust
- Wellcome Trust
- NHS Greater Glasgow and Clyde
- Sandwell and West Birmingham Hospitals NHS Trust
- Nottingham University Hospitals NHS Trust
- University Hospitals Bristol NHS Foundation Trust
- University Hospitals of Leicester NHS Trust
- Heart of England NHS Foundation Trust
- Royal Free London NHS Foundation Trust
- University Hospitals Plymouth NHS Trust
- National Institute for Health and Care Research (IS-BRC-0211-10046)
- University of Cambridge
- University of Southampton
- Imperial College London
- Imperial College Healthcare NHS Trust
- University College London
- Chelsea and Westminster Hospital NHS Foundation Trust
- Newcastle University
- University of Nottingham
- Cambridge University Hospitals
- Newcastle upon Tyne Hospitals NHS Foundation Trust
- Isaac Newton Trust
- North Bristol NHS Trust
- University College London Hospitals NHS Foundation Trust
- Norfolk and Norwich University Hospitals NHS Foundation Trust
- Sheffield Teaching Hospitals NHS Foundation Trust
- University Hospitals Coventry and Warwickshire NHS Trust
- Medical Research Council (MR/L001489/1, MR/K501037/1)
- Guy's and St Thomas' NHS Foundation Trust
- NIHR Newcastle Biomedical Research Centre (BH121729)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- primary biliary cirrhosis, quality of life, fatigue, social dysfunction, depression, symptom burden, health-related quality of life, symptom management, social networks
- MeSH terms
- Cross-Sectional Studies, Depression, Fatigue, Female, Humans, Liver Cirrhosis, Biliary, Male, Perception, Quality of Life, Surveys and Questionnaires, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
